Business Wire

Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings

4.11.2024 21:50:00 EET | Business Wire | Press release

Share

ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized pharmacovigilance (PV) expert Shelley Gandhi has joined the firm. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline compliance, manage risk, and accelerate time-to-market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104361511/en/

Shelley Gandhi joins ELIQUENT Life Sciences - bolsters expanded Pharmacovigilance & Risk Management Solutions (Photo: Business Wire)

“Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex regulatory challenges will be instrumental in expanding ELIQUENT’s pharmacovigilance solutions to meet the growing global demand for comprehensive safety and risk management across diverse markets,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.

Global Pharmacovigilance Expertise

Shelley Gandhi brings more than three decades of global PV and risk management experience to her role at ELIQUENT. Her extensive professional background includes more than 19 years of service at the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). During her tenure, Shelley served in multiple senior positions where she gained extensive knowledge of all European regulatory processes relating to monitoring the safety of licensed medicinal products and ancillary devices.

Shelley’s distinguished MHRA career included a role as the UK representative on the European Medicines Agency’s (EMA) EudraVigilance Expert Working Group. In this capacity, Shelley was instrumental in shaping EMA’s system for managing and analyzing information on suspected adverse reactions to medicines. Her contributions further enhanced key PV processes and systems across Europe.

Prior to joining ELIQUENT, Shelley served for more than 12 years as a strategic PV advisor to clients building and managing risk management systems. Shelley provided support to biotechnology clients across a broad range of therapeutic areas. Her experience includes strategic and technical advisory services in multiple markets from early clinical development to launch readiness.

At ELIQUENT, Shelley works with clients to ensure compliance with global safety standards, while anticipating changes, and preparing proactive solutions. Her deep understanding of drug safety and risk management protocols, coupled with her regulatory and industry experiences, amplifies ELIQUENT’s expanded PV and Risk Management Solutions. Learn more about Shelley.

Pharmacovigilance & Post-Market Surveillance Solutions

ELIQUENT’s expanded PV and Risk Management Solutions optimize practices to ensure consistency, compliance and operational efficiency across diverse markets. With decades of experience developed as leaders in both the public and private sectors, ELIQUENT’s industry-recognized PV experts support innovators with precision and expertise - enabling clients to confidently navigate global post-marketing surveillance, adverse event reporting, and risk management planning. Because there is no one-size-fits-all approach, each solution is built to support regulatory objectives, while aligning with evolving global demands. ELIQUENT’s customized global Pharmacovigilance & Risk Management Solutions include:

  • Global Support: Trusted guidance when navigating and complying with global PV regulations
  • Adverse Event Reporting: Systematic identification, objective analysis, and strategic guidance responding to unintended occurrences
  • Regulatory Reporting: Technical skill and institutional knowledge of complex regulatory reporting obligations
  • Signal Detection: Expert development and implementation of detection processes, including reporting and risk communication
  • Risk Assessment & Management: Proactive identification, assessment and planning to manage potential risk and ensure regulatory compliance
  • Post-Marketing Surveillance: Established network experts to support commercial product safety systems and reporting function
  • Risk Communications: Strategic development of communications plans to address emerging safety concerns and instill confidence in the market
  • Clinical Trials Safety Oversight: On-demand resources to support safety monitoring before and after regulatory approval
  • Qualified Person for Pharmacovigilance (QPPV): Comprehensive QPPV solutions ensure clients meet EU, UK, and regional pharmacovigilance requirements, while safeguarding patient safety.
  • Global PV Training: Bespoke pharmacovigilance training programs to uphold the highest regulatory standards across diverse global markets.

Integrated Solutions – Full-Service Support

ELIQUENT redefines regulatory consulting with a full-service platform that delivers integrated solutions across the product lifecycle. The firm's unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards. ELIQUENT's integrated platform of regulatory solutions feature the following integrated service offerings:

  • Regulatory Affairs Solutions: From the earliest phases of innovation through regulatory submissions, to post- approval support, ELIQUENT guides companies to approval and beyond.
  • Pharmacovigilance & Risk Management Solutions: With an approach that includes both strategic direction and hands-on global support, customized PV solutions empower companies to operate with confidence.
  • Quality & Compliance Solutions: Highly specialized compliance experts build customized solutions that equip companies with best- in-class strategic support, technical expertise, and project-based solutions.
  • Remediations Solutions: Respected professionals and global experts bring an unmatched level of credibility and trust when interacting with regulators and guiding companies to remediation solutions.
  • Talent Solutions: Whether you need a team of one or 100+, ELIQUENT’s talent solutions gives clients the ability to rapidly scale teams to the right size, with the right level of expertise, in the right locations.

About ELIQUENT Life Sciences

ELIQUENT Life Sciences is the fusion of six global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC. ­­ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for the products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.

Learn more about ELIQUENT Life Sciences at eliquent.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104361511/en/

Contacts

Taryn Fritz Walpole
twalpole@eliquent.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Unleash Raises $35M Led by One Peak to Help Enterprises Ship AI-driven Software Faster, Safer, and Smarter4.3.2026 16:00:00 EET | Press release

Unleash, the open-source FeatureOps company, today announced a $35 million Series B financing led by One Peak, with participation from existing investors Spark Capital, Frontline Ventures, and Firstminute Capital. The new funding will be used to accelerate product innovation and global expansion as enterprises confront the opportunities and risks of AI-accelerated software delivery. AI has dramatically accelerated software development, creating a generational opportunity for anyone in an enterprise to turn ideas, prompts, and prototypes into applications. But AI has also outpaced the systems designed to control software delivery. DORA research shows that a 25% rise in AI adoption correlates with a 7% drop in software stability. Enterprises are shipping code 2-3x faster with AI, yet outages caused by uncontrolled feature rollouts and missing kill switches are costing businesses millions in lost revenue, prolonged customer downtime, and brand damage. FeatureOps is emerging as the missing

Capcom’s Resident Evil Requiem Surpasses 5 Million Units!4.3.2026 16:00:00 EET | Press release

Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, surpassed 5 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304446142/en/ Resident Evil Requiem Logo Resident Evil Requiem is the latest installment in the Resident Evil series, which celebrates its 30th anniversary this month. The title successfully elevated the essence of survival horror by heightening the interplay between intense fear and exhilarating action. Resident Evil Requiem was developed using RE ENGINE, Capcom’s proprietary game engine, which allowed the company to deliver visuals in photorealistic detail, including the characters’ skin, teary eyes, and flowing hair, as well as the translucency of light. In addition, the title offers a new game experience for a broad fanbase through multiple difficulty settings that accommodate everyone from newcomers to experienced players,

Siren Fusion 2026: The Convergence of People, Technology and Ideas4.3.2026 15:30:00 EET | Press release

Siren today announced Siren Fusion 2026, its inaugural global summit convening senior investigators, national security leaders and AI innovators for a high-trust forum on the future of investigative intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304240853/en/ Siren Fusion 2026 is the convergence of people, technology and ideas, in Galway, Ireland. An invitation-only summit for global intelligence, national security and investigative leaders. Taking place in Galway, Ireland, Fusion is the deliberate convergence of people, technology and ideas within a national security frame. Structured as an educational and strategic forum rather than a conventional conference, Fusion 2026 focuses on the issues that now define the intelligence and law enforcement agenda: Geopolitical instability AI-driven investigative transformation Cognitive warfare and influence operations Entity resolution and data integrity at scale The

Mary Kay Goes for Gold in Global Manufacturing Standards4.3.2026 15:11:00 EET | Press release

Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, has achieved ISO 22716 certification, the internationally recognized gold standard for cosmetic Good Manufacturing Practices (GMP), reinforcing the company’s unwavering commitment to product quality, safety, and consumer trust worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304100367/en/ Chaun Harper, Chief Supply Chain Officer at Mary Kay Inc., emphasized the broader significance of the milestone: “At Mary Kay, quality is not a checkbox – it is a promise, an operational framework, and a culture. (Photo Credit: Mary Kay Inc.) Key Data Points About Mary Kay’s Global Manufacturing: Built on 26 acres of land, Mary Kay’s state-of-the-art, Silver LEED-certified Richard R. Rogers Manufacturing and R&D Center (R3) is located in Lewisville, Texas. R3 is a $100+ million investment and is a 453,000-square-foot building. R3 has the capability to

NelsonHall Recognizes LTM as a Leader in GenAI & Process Automation for Banking4.3.2026 14:45:00 EET | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as a Leader in the ‘Overall’ market segment in the NelsonHall NEAT Evaluation for GenAI & Process Automation in Banking 2025. In the NEAT framework, Leaders are vendors that demonstrate high capability relative to peers in delivering immediate client benefit while also meeting future client requirements. The recognition positions LTM among the top-performing vendors evaluated for their ability to deliver both immediate business impact and long-term innovation capability in GenAI and process automation services for the banking sector. The evaluation highlights LTM’s depth of experience in financial services, which accounts for a large portion of its overall revenues, and its focused investments in GenAI, agentic AI, and process automation capabilities delivered through its BlueVerse™ platform. LTM has digital agents dedicated to manage GenAI and process automation services, supporting banking cl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye